News & Updates

Treatment of symptomatic COVID-19 with nirmatrelvir/ritonavir in children at least 6 years of age who are at risk of progression to severe disease appears to be safe and well-tolerated, with pharmacokinetic data from the open-label phase 2/3 EPIC-Peds* study indicating suitable dosing regimens for two distinct weight categories of this population.

Ultra-low-dose 0.005 % estriol vaginal gel helps reduce the incidence of recurrent urinary tract infections (UTIs) and improve vaginal pH in postmenopausal women with genitourinary syndrome of menopause (GSM), as reported in a study.